Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02614586 · ClinicalTrials.gov registry record · Phase 1
Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02614586 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 11 participants.
The verdict
NCT02614586, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether improvement in P50 (a pharmacodynamic marker) in auditory sensory gating is demonstrated after administration of TAK-058 and ondansetron compared to placebo in participants with schizophrenia.
Interventions
- DRUG Ondansetron
- DRUG Ondansetron Placebo
- DRUG TAK-058
- DRUG TAK-058 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02614586
The ClinicalTrials.gov registry entry for NCT02614586 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ondansetron is the first listed.
NCT02614586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02614586 about?
NCT02614586 is a clinical study titled "Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia". The purpose of this study is to determine whether improvement in P50 (a pharmacodynamic marker) in auditory sensory gating is demonstrated after administration of TAK-058 and ondansetron compared to placebo in participants with schizophrenia.
What is the current status of trial NCT02614586?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2015-12. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02614586?
The interventions under investigation include: Ondansetron (DRUG), Ondansetron Placebo (DRUG), TAK-058 (DRUG), TAK-058 Placebo (DRUG).
Who is sponsoring clinical trial NCT02614586?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.